more

AVROBIO (AVRO)

(Delayed Data from NSDQ)

$1.19 USD

-0.02 (-1.65%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $1.19 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.20%
2	Buy	18.04%
3	Hold	9.52%
4	Sell	5.20%
5	Strong Sell	2.60%
S&P	500	11.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth C Momentum F VGM

Industry Rank:

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is AVROBIO (AVRO) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research Published on November 08,2023

Here is how AVROBIO, Inc. (AVRO) and Crinetics Pharmaceuticals, Inc. (CRNX) have performed compared to their sector so far this year.

Is AVROBIO (AVRO) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research Published on October 23,2023

Here is how AVROBIO, Inc. (AVRO) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.

Has AVROBIO (AVRO) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research Published on October 06,2023

Here is how AVROBIO, Inc. (AVRO) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.

AVROBIO (AVRO) to Explore Strategic Options, Stock Rises 46%

by Zacks Equity Research Published on July 13,2023

AVROBIO (AVRO) announces its decision to halt all development programs in its quest to explore strategic alternatives. The stock of the company surges 46% in response on Wednesday.

biotechs

AVROBIO (AVRO) Stock Up on Upbeat Data From Cystinosis Study

by Zacks Equity Research Published on May 18,2022

Results from AVROBIO's (AVRO) phase I/II study, which is evaluating its gene-therapy candidate for cystinosis, show the latter's potential to stabilize or reduce the impact of cystinosis on different tissues.

bluebird (BLUE) Undertakes Restructuring Moves to Curb Cash Burn

by Zacks Equity Research Published on April 06,2022

bluebird (BLUE) intends to reduce the existing workforce by nearly 30% to reduce 2022 operating expenses by 35-40%. This is likely to generate cost savings of $160 million over two years.

Corcept (CORT) Completes Enrolment in Mid-Stage Weight Gain Study

by Zacks Equity Research Published on April 05,2022

Corcept (CORT) completes enrolling patients in a phase II study on miricorilant for treating recent antipsychotic-induced weight gain. Data from this study is expected in fourth-quarter 2021.

Theravance's (TBPH) Hypotension Study Misses Primary Goal

by Zacks Equity Research Published on April 05,2022

Theravance's (TBPH) phase III study on ampreloxetine for treating symptomatic nOH fails to meet its goal. The study benefitted patients with a rare neurodegenerative disorder.

Walgreens Boots (WBA) Q2 Earnings Top Estimates, Margins Up

by Zacks Equity Research Published on April 01,2022

Strong execution across business segments, led by COVID-19 vaccinations and testing, drove Walgreens' (WBA) fiscal second-quarter top line.

Here's Why AVROBIO, Inc. (AVRO) is Poised for a Turnaround After Losing 19.7% in 4 Weeks

by Zacks Equity Research Published on February 03,2022

The heavy selling pressure might have exhausted for AVROBIO, Inc. (AVRO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

AVRONegative Net Change

Bears are Losing Control Over AVROBIO, Inc. (AVRO), Here's Why It's a 'Buy' Now

by Zacks Equity Research Published on January 25,2022

AVROBIO, Inc. (AVRO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

AVRONegative Net Change

Here's Why AVROBIO, Inc. (AVRO) is Poised for a Turnaround After Losing 44.1% in 4 Weeks

by Zacks Equity Research Published on January 07,2022

AVROBIO, Inc. (AVRO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

AVRONegative Net Change

4 Biotech Stocks Set to Outpace Q1 Earnings Estimates

by Zacks Equity Research Published on May 13,2021

Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.

biotechs

GT Biopharma (GTBP) to Report Q1 Earnings: What to Expect?

by Zacks Equity Research Published on May 13,2021

GT Biopharma (GTBP) is expected to provide updates on its pipeline development when it reports first-quarter 2021 result.

biotechs

Is a Surprise Coming for AVROBIO (AVRO) This Earnings Season?

by Zacks Equity Research Published on May 12,2021

AVROBIO (AVRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

AVRONegative Net Change

Bionano (BNGO) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research Published on May 10,2021

Bionano Genomics (BNGO) is expected to provide updates on its earnings and revenues when it reports first-quarter 2021 result.

biotechs

AVROBIO, Inc. (AVRO) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research Published on April 20,2021

AVROBIO, Inc. (AVRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.